These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35235944)

  • 1. Antispacer peptide nucleic acids for sequence-specific CRISPR-Cas9 modulation.
    Economos NG; Quijano E; Carufe KEW; Perera JDR; Glazer PM
    Nucleic Acids Res; 2022 Jun; 50(10):e59. PubMed ID: 35235944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide Nucleic Acid-Mediated Regulation of CRISPR-Cas9 Specificity.
    Carufe KEW; Economos NG; Glazer PM
    Nucleic Acid Ther; 2024 Oct; 34(5):245-256. PubMed ID: 39037032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a gRNA Expression and Processing Platform for Efficient CRISPR-Cas9-Based Gene Editing and Gene Silencing in Candida tropicalis.
    Li Y; Zhang L; Yang H; Xia Y; Liu L; Chen X; Shen W
    Microbiol Spectr; 2022 Jun; 10(3):e0005922. PubMed ID: 35543560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction and Validation of Native and Engineered Cas9 Guide Sequences.
    Briner AE; Henriksen ED; Barrangou R
    Cold Spring Harb Protoc; 2016 Jul; 2016(7):. PubMed ID: 27371591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR-Cas "Non-Target" Sites Inhibit On-Target Cutting Rates.
    Moreb EA; Hutmacher M; Lynch MD
    CRISPR J; 2020 Dec; 3(6):550-561. PubMed ID: 33346713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A catalogue of biochemically diverse CRISPR-Cas9 orthologs.
    Gasiunas G; Young JK; Karvelis T; Kazlauskas D; Urbaitis T; Jasnauskaite M; Grusyte MM; Paulraj S; Wang PH; Hou Z; Dooley SK; Cigan M; Alarcon C; Chilcoat ND; Bigelyte G; Curcuru JL; Mabuchi M; Sun Z; Fuchs RT; Schildkraut E; Weigele PR; Jack WE; Robb GB; Venclovas Č; Siksnys V
    Nat Commun; 2020 Nov; 11(1):5512. PubMed ID: 33139742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-Cas9 off-targeting assessment with nucleic acid duplex energy parameters.
    Alkan F; Wenzel A; Anthon C; Havgaard JH; Gorodkin J
    Genome Biol; 2018 Oct; 19(1):177. PubMed ID: 30367669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A method to convert mRNA into a gRNA library for CRISPR/Cas9 editing of any organism.
    Arakawa H
    Sci Adv; 2016 Aug; 2(8):e1600699. PubMed ID: 27574704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precision Genome Editing with CRISPR-Cas9.
    Rahman S; Ikram AR; Azeem F; Tahir Ul Qamar M; Shaheen T; Mehboob-Ur-Rahman
    Methods Mol Biol; 2024; 2788():355-372. PubMed ID: 38656525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of the affinities of CRISPR-Cas9 nucleases for cognate protospacer adjacent motif (PAM) sequences.
    Mekler V; Kuznedelov K; Severinov K
    J Biol Chem; 2020 May; 295(19):6509-6517. PubMed ID: 32241913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene Manipulation Using Fusion Guide RNAs for Cas9 and Cas12a.
    Shin HR; Kweon J; Kim Y
    Methods Mol Biol; 2021; 2162():185-193. PubMed ID: 32926383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved gRNA secondary structures allow editing of target sites resistant to CRISPR-Cas9 cleavage.
    Riesenberg S; Helmbrecht N; Kanis P; Maricic T; Pääbo S
    Nat Commun; 2022 Jan; 13(1):489. PubMed ID: 35078986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guide RNAs: A Glimpse at the Sequences that Drive CRISPR-Cas Systems.
    Briner AE; Barrangou R
    Cold Spring Harb Protoc; 2016 Jul; 2016(7):. PubMed ID: 27371605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programming PAM antennae for efficient CRISPR-Cas9 DNA editing.
    Wang F; Hao Y; Li Q; Li J; Zhang H; Zhang X; Wang L; Bustamante C; Fan C
    Sci Adv; 2020 May; 6(19):eaay9948. PubMed ID: 32494703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of genome editing through CRISPR-Cas9 engineering.
    Zhang JH; Adikaram P; Pandey M; Genis A; Simonds WF
    Bioengineered; 2016 Apr; 7(3):166-74. PubMed ID: 27340770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationally Designed Anti-CRISPR Nucleic Acid Inhibitors of CRISPR-Cas9.
    Barkau CL; O'Reilly D; Rohilla KJ; Damha MJ; Gagnon KT
    Nucleic Acid Ther; 2019 Jun; 29(3):136-147. PubMed ID: 30990769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.
    Johansen AK; Molenaar B; Versteeg D; Leitoguinho AR; Demkes C; Spanjaard B; de Ruiter H; Akbari Moqadam F; Kooijman L; Zentilin L; Giacca M; van Rooij E
    Circ Res; 2017 Oct; 121(10):1168-1181. PubMed ID: 28851809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spatiotemporal Control of CRISPR/Cas9 Function in Cells and Zebrafish using Light-Activated Guide RNA.
    Zhou W; Brown W; Bardhan A; Delaney M; Ilk AS; Rauen RR; Kahn SI; Tsang M; Deiters A
    Angew Chem Int Ed Engl; 2020 Jun; 59(23):8998-9003. PubMed ID: 32160370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modification of Cas9, gRNA and PAM: Key to further regulate genome editing and its applications.
    Gupta R; Gupta D; Ahmed KT; Dey D; Singh R; Swarnakar S; Ravichandiran V; Roy S; Ghosh D
    Prog Mol Biol Transl Sci; 2021; 178():85-98. PubMed ID: 33685601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.